Long-term follow-up after pediatric hematopoietic stem cell transplantation
DOI:
https://doi.org/10.46765/2675-374X.2025v6n1e286Keywords:
Follow-Up Studies, Cancer Survivors, Long TermAbstract
This article, part of the Pediatric Group consensus of the Brazilian Society of Bone Marrow Transplantation, addresses lifelong follow-up in pediatric hematopoietic stem cell transplant survivors. With the growing number of long-term survivors, specialized monitoring is essential, especially for high-risk groups such as infants, recipients of total body irradiation, and those with inherited bone marrow failure syndromes. The consensus outlines surveillance strategies for detecting and managing late complications, including chronic graft-versus-host disease and secondary effects. Multidisciplinary recommendations aim to optimize early intervention and quality of life, establishing a standardized follow-up framework for pediatric transplant care in Brazil.
References
1. Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale GA, Horn B, Kelly D, Liu H, Rowley S, Schoemans H, Shah A, Lupo Stanghellini MT, Agrawal V, Ahmed I, Ali A, Bhatt N, Byrne M, Chhabra S, DeFilipp Z, Fahnehjelm K, Farhadfar N, Horn E, Lee C, Nathan S, Penack O, Prasad P, Rotz S, Rovó A, Yared J, Pavletic S, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, Shaw BE, Petriček I. Non-graft-versus-host disease ocular complications after hematopoietic cell transplantation: expert review from the late effects and quality of life working committee of the center for international blood and marrow transplant research and the transplant complications working party of the European society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2019;25(2):e46-e54. https://doi.org/10.1016/j.bbmt.2018.11.021 DOI: https://doi.org/10.1016/j.bbmt.2018.11.021
2. Lee SL, Nguyen QN, Ho C, James S, Kaur A, Lim A, Tiedemann K, Zacharin M. The late effects of hematopoietic stem cell transplants in pediatric patients: a 25-year review. J Clin Endocrinol Metab. 2025;110(2):e347-62. https://doi.org/10.1210/clinem/dgae196 DOI: https://doi.org/10.1210/clinem/dgae196
3. Hoehn ME, Vestal R, Calderwood J, Gannon E, Cook B, Rochester R, Hartford C, Triplett B, Sunkara A, Kang G, Walton RC. Ocular complications in school-age children and adolescents after allogeneic bone marrow transplantation. Am J Ophthalmol. 2020;213:153-60. https://doi.org/10.1016/j.ajo.2020.01.025 DOI: https://doi.org/10.1016/j.ajo.2020.01.025
4. Hoehn ME, Calderwood J, Gannon E, Cook B, Rochester R, Hartford C, Triplett B, Sunkara A, Kang G, Walton RC. Ocular complications in a young pediatric population following bone marrow transplantation. J Am Assoc Pediatr Ophthalmol Strabismus. 2018;22(2):102-106.e1. https://doi.org/10.1016/j.jaapos.2017.10.010 DOI: https://doi.org/10.1016/j.jaapos.2017.10.010
5. van der Pas-van Voskuilen IG, Veerkamp JS, Raber-Durlacher JE, Bresters D, van Wijk AJ, Barasch A, McNeal S, Gortzak RA. Long-term adverse effects of hematopoietic stem cell transplantation on dental development in children. Support Care Cancer. 2009;17(9):1169-75. https://doi.org/10.1007/s00520-008-0567-1 DOI: https://doi.org/10.1007/s00520-008-0567-1
6. Haverman TM, Raber-Durlacher JE, Rademacher WM, Vokurka S, Epstein JB, Huisman C, Hazenberg MD, de Soet JJ, de Lange J, Rozema FR. Oral complications in hematopoietic stem cell recipients: the role of inflammation. Mediators Inflamm. 2014;2014:378281. https://doi.org/10.1155/2014/378281 DOI: https://doi.org/10.1155/2014/378281
7. Majhail NS, Rizzo JD. Surviving the cure: long term followup of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2013;48(9):1145-51. https://doi.org/10.1038/bmt.2012.258 DOI: https://doi.org/10.1038/bmt.2012.258
8. Fred Hutchinson Cancer Center. Long-term follow-up after hematopoietic stem cell transplant: general guidelines for referring physicians. Seattle: Fred Hutchinson Cancer Center; 2024.
9. Lopes Garcia J, Vaz De Macedo A, Dorini Pelegrina PR, Barbosa Tavares RDC, Vasconcelos Gouveia R, Seber A. Long-term follow-up of pediatric patients undergoing hematopoietic stem cell transplantation. J Bone Marrow Transplant Cell Ther. 2021;2(4):142. https://doi.org/10.46765/2675-374X.2021v2n4p142 DOI: https://doi.org/10.46765/2675-374X.2021v2n4p142
10. Rotz SJ, Bhatt NS, Hamilton BK, Duncan C, Aljurf M, Atsuta Y, Beebe K, Buchbinder D, Burkhard P, Carpenter PA, Chaudhri N, Elemary M, Elsawy M, Guilcher GM, Hamad N, Karduss A, Peric Z, Purtill D, Rizzo D, Rodrigues M, Ostriz MBR, Salooja N, Schoemans H, Seber A, Sharma A, Srivastava A, Stewart SK, Baker KS, Majhail NS, Phelan R. International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update. Bone Marrow Transplant. 2024;30(4):349-85. https://doi.org/10.1016/j.jtct.2023.12.001 DOI: https://doi.org/10.1016/j.jtct.2023.12.001
11. Galaverna F, Baccelli F, Zama D, Tridello G, Masetti R, Soncini E, Mura R, Barzaghi F, Colombini A, Prunotto G, D’Amico MR, Calore E, Biffi A, Perruccio K, Gasperini P, Oltolini C, Quagliarella F, Giacomazzi A, Pagliara D, Locatelli F, Cesaro S. Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (IEOP). Bone Marrow Transplant. 2024;59(4):505-12. https://doi.org/10.1038/s41409-024-02209-2 DOI: https://doi.org/10.1038/s41409-024-02209-2
12. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2005;11(12):945-56. https://doi.org/10.1016/j.bbmt.2005.09.004 DOI: https://doi.org/10.1016/j.bbmt.2005.09.004
13. Campo LD, León NG, Palacios DC, Lagana C, Tagarro D. Abdominal complications following hematopoietic stem cell transplantation. RadioGraphics. 2014;34(2):396-412. https://doi.org/10.1148/rg.342135046 DOI: https://doi.org/10.1148/rg.342135046
14. Strasser SI, Shulman HM, Flowers ME, Reddy R, Margolis DA, Prumbaum M, Seropian SE, McDonald GB. Chronic graft-versus-host disease of the liver: presentation as an acute hepatitis. Hepatology. 2000;32(6):1265-71. https://doi.org/10.1053/jhep.2000.20067 DOI: https://doi.org/10.1053/jhep.2000.20067
15. Gentile G, Antonelli G. HBV reactivation in patients undergoing hematopoietic stem cell transplantation: a narrative review. Viruses. 2019;11(11):1049. https://doi.org/10.3390/v11111049 DOI: https://doi.org/10.3390/v11111049
16. Nava T, Ansari M, Dalle JH, de Heredia CD, Güngör T, Trigoso E, Falkenberg U, Bertaina A, Gibson B, Jarisch A, Balduzzi A, Boenig H, Krivan G, Vettenranta K, Matic T, Buechner J, Kalwak K, Lawitschka A, Yesilipek A, Lucchini G, Peters C, Turkiewicz D, Niinimäki R, Diesch T, Lehrnbecher T, Sedlacek P, Hutt D, Dalissier A, Wachowiak J, Yaniv I, Stein J, Yalçin K, Sisinni L, Deiana M, Ifversen M, Kuhlen M, Meisel R, Bakhtiar S, Cesaro S, Willasch A, Corbacioglu S, Bader P. Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2020;55(6):1126-36. https://doi.org/10.1038/s41409-020-0818-4 DOI: https://doi.org/10.1038/s41409-020-0818-4
17. Cattoni A, Capitoli G, Casagranda S, Corti P, Adavastro M, Molinaro A, Di Gennaro F, Bonanomi S, Biondi A, Galimberti S, Balduzzi A. Iron overload following hematopoietic stem cell transplantation: prevalence, severity, and management in children and adolescents with malignant and nonmalignant diseases. Transplant Cell Ther. 2023;29(4):271.e1-271.e12. https://doi.org/10.1016/j.jtct.2023.01.020 DOI: https://doi.org/10.1016/j.jtct.2023.01.020
18. Tenneti P, Chojecki A, Knovich MA. Iron overload in the HCT patient: a review. Bone Marrow Transplant. 2021;56(8):1794-804. https://doi.org/10.1038/s41409-021-01244-7 DOI: https://doi.org/10.1038/s41409-021-01244-7
19. Dulamea A, Lupescu I. Neurological complications of hematopoietic cell transplantation in children and adults. Neural Regen Res. 2018;13(6):945-54. https://doi.org/10.4103/1673-5374.233431 DOI: https://doi.org/10.4103/1673-5374.233431
20. Perkins JL, Kunin-Batson AS, Youngren NM, Ness KK, Ulrich KJ, Hansen MJ, Petryk A, Steinberger J, Anderson FS, Baker KS. Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer. 2007;49(7):958-63. https://doi.org/10.1002/pbc.21207 DOI: https://doi.org/10.1002/pbc.21207
21. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, Okamoto S, Seber A, Socie G, Szer J, Van Lint MT, Wingard JR, Tichelli A; Center for International Blood and Marrow Transplant Research; American Society for Blood and Marrow Transplantation; European Group for Blood and Marrow Transplantation; Asia-Pacific Blood and Marrow Transplantation Group; Bone Marrow Transplant Society of Australia and New Zealand; East Mediterranean Blood and Marrow Transplantation Group; Sociedade Brasileira de Transplante de Medula Ossea. Recommended screening and preventive practices for longterm survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47(3):337-41. https://doi.org/10.1038/bmt.2012.5 DOI: https://doi.org/10.1038/bmt.2012.5
22. Dowling MR, Li S, Dey BR, McAfee SL, Hock HR, Spitzer TR, Chen YB, Ballen KK. Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact. Bone Marrow Transplant. 2018;53(2):199-206. https://doi.org/10.1038/bmt.2017.239 DOI: https://doi.org/10.1038/bmt.2017.239
23. Sharafeldin N, Bosworth A, Patel SK, Chen Y, Morse E, Mather M, Sun C, Francisco L, Forman SJ, Wong FL, Bhatia S. Cognitive functioning after hematopoietic cell transplantation for hematologic malignancy: results from a prospective longitudinal study. J Clin Oncol. 2018;36(5):463-75. https://doi.org/10.1200/jco.2017.74.2270 DOI: https://doi.org/10.1200/JCO.2017.74.2270
24. Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, Shaw BE. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018;24(2):228-41. https://doi.org/10.1016/j.bbmt.2017.09.004 DOI: https://doi.org/10.1016/j.bbmt.2017.09.004
25. Kang JM, Kim YJ, Kim JY, Cho EJ, Lee JH, Lee MH, Lee SH, Sung KW, Koo HH, Yoo KH. Neurologic complications after allogeneic hematopoietic stem cell transplantation in children: analysis of prognostic factors. Biol Blood Marrow Transplant. 2015;21(6):1091-8. https://doi.org/10.1016/j.bbmt.2015.02.007 DOI: https://doi.org/10.1016/j.bbmt.2015.02.007
26. Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: hematopoietic stem cell transplantation and cellular therapies. Cham: Springer International; 2019. DOI: https://doi.org/10.1007/978-3-030-02278-5
27. Sociedade Brasileira de Pediatria. Complicações endócrinas do tratamento oncológico na infância: informações para o pediatra. Rev Med Minas Gerais. 2010;20(4 Suppl. 3):S54-S58.
28. Yen KT, Lee AS, Krowka MJ, Burger CD. Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment. Clin Chest Med. 2004;25(1):189-201. https://doi.org/10.1016/s0272-5231(03)00121-7 DOI: https://doi.org/10.1016/S0272-5231(03)00121-7
29. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1. https://doi.org/10.1016/j.bbmt.2014.12.001 DOI: https://doi.org/10.1016/j.bbmt.2014.12.001
30. Tichelli A, Passweg J, Wójcik D, Rovó A, Harousseau JL, Masszi T, Zander A, Békássy A, Crawley C, Arat M, Sica S, Lutz P, Socié G; EBMT Late Effects Working Party. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93(8):1203-10. https://doi.org/10.3324/haematol.12949 DOI: https://doi.org/10.3324/haematol.12949
31. Tichelli A, Rovó A, Gratwohl A. Late pulmonary, cardiovascular, and renal complications after hematopoietic stem cell transplantation and recommended screening practices. Hematology. 2008:125-33. https://doi.org/10.1182/asheducation-2008.1.125 DOI: https://doi.org/10.1182/asheducation-2008.1.125
32. Majhail NS, Flowers ME, Ness KK, Jagasia M, Carpenter PA, Arora M, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2009;43(1):49-54. https://doi.org/10.1038/bmt.2008.263 DOI: https://doi.org/10.1038/bmt.2008.263
33. Brasil. Ministério da Saúde. Manual dos Centros de Referência para Imunobiológicos Especiais. 6ª ed. Brasília: Ministério da Saúde; 2024.
34. Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, de Lavallade H, Gallo G, Lehrnbecher T, Engelhard D, Ljungman P; European Conference on Infections in Leukaemia group. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(6):e200-12. https://doi.org/10.1016/s1473-3099(18)30600-5 DOI: https://doi.org/10.1016/S1473-3099(18)30600-5
35. Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, Kelkar AH, Law LY, LeFebvre KB, Ljungman P, Miller ED, Meyer LA, Moore HN, Soares HP, Taplitz RA, Woldetsadik ES, Kohn EC. Vaccination of adults with cancer: ASCO Guideline. J Clin Oncol. 2024;42(14):1699-721. https://doi.org/10.1200/jco.24.00032 DOI: https://doi.org/10.1200/JCO.24.00032
36. Schuster JE, Hamdan L, Dulek DE, Kitko CL, Batarseh E, Haddadin Z, Stewart LS, Stahl A, Potter M, Rahman H, Kalams SA, Bocchini CE, Moulton EA, Coffin SE, Ardura MI, Wattier RL, Maron G, Grimley M, Paulsen G, Harrison CJ, Freedman JL, Carpenter PA, Englund JA, Munoz FM, Danziger-Isakov L, Spieker AJ, Halasa NB; Pediatric HCT Flu Study. The durability of antibody responses of two doses of high-dose relative to two doses of standard-dose inactivated influenza vaccine in pediatric hematopoietic cell transplant recipients: a multicenter randomized controlled trial. Clin Infect Dis. 2024;78(1):217-26. https://doi.org/10.1093/cid/ciad534 DOI: https://doi.org/10.1093/cid/ciad534
37. Sociedade Brasileira de Imunizações. Calendário de vacinas para pacientes especiais. São Paulo: Sociedade Brasileira de Imunizações; 2024.
38. Maiolino MG, Carlesse F, Ramos JF. Prevention and treatment of infectious complications post HSCT. J Bone Marrow Transplant Cell Ther. 2021;2(1):197-217. https://doi.org/10.46765/2675-374X.2021v4n1p197-217 DOI: https://doi.org/10.46765/2675-374X.2021v4n1p197-217
39. Association of Clinical Psychologists, Anthony Nolan. Guidelines for the role of psychological specialists in the assessment of adults undergoing haematopoietic stem cell transplantation. London: Anthony Nolan; 2024.
40. Amonoo HL, Brown LA, Scheu CF, Millstein RA, Pirl WF, Vitagliano HL, Antin JH, Huffman JC. Positive psychological experiences in allogeneic hematopoietic stem cell transplantation. Psychooncology. 2019;28(8):1633-9. https://doi.org/10.1002/pon.5128 DOI: https://doi.org/10.1002/pon.5128
41. Bhatt NS, Brazauskas R, Salit RB, Syrjala K, Bo-Subait S, Tecca H, Badawy SM, Baker KS, Beitinjaneh A, Bejanyan N, Byrne M, Dias A, Farhadfar N, Freytes CO, Ganguly S, Hashmi S, Hayashi RJ, Hong S, Inamoto Y, Jamani K, Kasow KA, Khera N, Krem MM, Lazarus HM, Lee CJ, Lee S, Majhail NS, Malone AK, Marks DI, Mau LW, Mayo SJ, Muffly LS, Nathan S, Nishihori T, Page KM, Preussler J, Rangarajan HG, Rotz SJ, Salooja N, Savani BN, Schears R, Schechter-Finkelstein T, Schiller G, Shah AJ, Sharma A, Wang T, Wirk B, Battiwalla M, Schoemans H, Hamilton B, Buchbinder D, Phelan R, Shaw B. Return to work among young adult survivors of allogeneic hematopoietic cell transplantation in the United States. Transplant Cell Ther. 2021;27(8):679. e1-679.e8. https://doi.org/10.1016/j.jtct.2021.04.013 DOI: https://doi.org/10.1016/j.jtct.2021.04.013
42. Lugthart G, Jordans CCE, de Pagter APJ, Bresters D, Jol-van der Zijde CM, Bense JE, van Rooij-Kouwenhoven RWG, Sukhai RN, Louwerens M, Dorresteijn EM, Lankester AC. Chronic kidney disease ten years after pediatric allogeneic hematopoietic stem cell transplantation. Kidney Int. 2021;100(4):906-14. https://doi.org/10.1016/j.kint.2021.05.030 DOI: https://doi.org/10.1016/j.kint.2021.05.030
43. Hingorani S. Renal complications of hematopoietic-cell transplantation. N Engl J Med. 2016;374(23): 2256-67. https://doi.org/10.1056/nejmra1404711 DOI: https://doi.org/10.1056/NEJMra1404711
44. Renaghan AD, Costa JM, Esteves A. Kidney disease and hematopoietic stem cell transplantation. Kidney360. 2025;6(2):317-30. https://doi.org/10.34067/kid.0000000692 DOI: https://doi.org/10.34067/KID.0000000692
45. Higham CS, Shimano KA, Kharbanda S, Chu J, Cisneros GS, Winestone LE, Dara J, Huang JN, Hermiston ML, Long-Boyle JR, Dvorak CC. Cyclophosphamide and thiotepa increases risk of transplant associated thrombotic microangiopathy. Transplant Cell Ther. 2024;30(9):931.e1-931.e10. https://doi.org/10.1016/j.jtct.2024.06.020 DOI: https://doi.org/10.1016/j.jtct.2024.06.020
46. Schoettler ML, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S, Moissev I, Sanchez-Ortega I, Srivastava A, Atsuta Y, Carpenter P, Koreth J, Kroger N, Ljungman P, Page K, Popat U, Shaw BE, Sureda A, Soiffer R, Vasu S. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantationassociated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2023;29(3):151-63. https://doi.org/10.1016/j.jtct.2022.11.015 DOI: https://doi.org/10.1016/j.jtct.2022.11.015
47. Higham CS, Collins G, Shimano KA, Melton A, Kharbanda S, Winestone LE, Huang JN, Dara J, Long- Boyle JR, Dvorak CC. Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis. Blood Adv. 2021;5(8):2106-12. https://doi.org/10.1182/bloodadvances.2020003988 DOI: https://doi.org/10.1182/bloodadvances.2020003988
48. Pan T, Qi J, Tang Y, Yao Y, Chen J, Wang H, Yang J, Xu X, Shi Q, Liu Y, He X, Chen F, Ma X, Hu X, Wu X, Wu D, Han Y. N-acetylcysteine as prophylactic therapy for transplantation-associated thrombotic microangiopathy: a randomized, placebo-controlled trial. Transplant Cell Ther. 2022;28(11):764.e1-764.e7. https://doi.org/10.1016/j.jtct.2022.07.029 DOI: https://doi.org/10.1016/j.jtct.2022.07.029
49. Kwon DH, Jung S, Lee EJ, Lee JY, Moon S, Lee JW, Chung NG, Cho B, Kim HK. Incidence and risk factors for early-onset hypertension after allogeneic hematopoietic stem cell transplantation in children. Korean Circ J. 2013;43(12):804-10. https://doi.org/10.4070/kcj.2013.43.12.804 DOI: https://doi.org/10.4070/kcj.2013.43.12.804
50. Bonfim C. Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes. Hematology Am Soc Hematol Educ Program. 2020; 2020(1):107-14. https://doi.org/10.1182/hematology.2020000095 DOI: https://doi.org/10.1182/hematology.2020000095
51. National Marrow Donor Program / Be The Match. Post-Transplant Care. National Marrow Donor Program/Be The Match [cited 2025 Apr 30]. Available from: https://network.nmdp.org/services-support/hematologyoncology/post-transplant-care
52. Singavi AK, Harrington AM, Fenske TS. Post-transplant lymphoproliferative disorders. Cancer Treat Res. 2015;165:305-27. https://doi.org/10.1007/978-3-319-13150-4_13 DOI: https://doi.org/10.1007/978-3-319-13150-4_13
53. Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173-83. https://doi.org/10.1007/s11899-013-0162-5 DOI: https://doi.org/10.1007/s11899-013-0162-5
54. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol. 2005;56(1):155-67. https://doi.org/10.1016/j.critrevonc.2005.03.015 DOI: https://doi.org/10.1016/j.critrevonc.2005.03.015
55. McDonald RA, Smith JM, Ho M, Lindblad R, Ikle D, Grimm P, Wyatt R, Arar M, Liereman D, Bridges N, Harmon W; CCTPT Study Group. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant. 2008;8(5):984-9. https://doi.org/10.1111/j.1600-6143.2008.02167.x DOI: https://doi.org/10.1111/j.1600-6143.2008.02167.x
56. Curtis RE, Travis LB, Rowlings PA, Socié G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP, Hoover RN, Fraumeni JF Jr, Deeg HJ. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94(7):2208-16.
57. Abbas F, El Kossi M, Shaheen IS, Sharma A, Halawa A. Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches. World J Transplant. 2020;10(2):29-46. https://doi.org/10.5500/wjt.v10.i2.29 DOI: https://doi.org/10.5500/wjt.v10.i2.29
58. Ferreiro JF, Morscio J, Dierickx D, Vandenberghe P, Gheysens O, Verhoef G, Zamani M, Tousseyn T, Wlodarska I. EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features. Am J Transplant. 2016;16(2):414-25. https://doi.org/10.1111/ajt.13558 DOI: https://doi.org/10.1111/ajt.13558
59. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017.
60. Clerico M, Dogliotti I, Aroldi A, Consoli C, Giaccone L, Bruno B, Cavallo F. Post-transplant lymphoproliferative disease (PTLD) after allogeneic hematopoietic stem cell transplantation: biology and treatment options. J Clin Med. 2022;11(24):7542. https://doi.org/10.3390/jcm11247542 DOI: https://doi.org/10.3390/jcm11247542
61. Marks DI, Davies AJ, Stiller C, van der Werff Ten Bosch J, Sienie CA, Ebell W, Veys P, Cohen A, Rao K, Ifrah N, Lehrnbecher T, Korthof E, Schellong G, Pillon M, Andolina M, Balduzzi A, Beauchemin H, Boelens JJ, Boztug H, Buechner J, Chevret S, Coman T, Diaz-de-Heredia C, Dvorak CC, Faraci M, Felice M, Furtwängler R, Gámez P, Gennery A, Greil J, Grigore E, Ifrah N, Locatelli F, Nöllke P, Peters C, Sakashita E, Simonova E, Slatter M, Stepensky P, Tse W, Veys P, Wimmer G, Winiarski J, Wynn R, Yoshimi A, Treleaven JG, Magrath IT, Norton AJ, Shannon-Lowe C. The use of rituximab in pediatric PTLD: a multicenter study. Lancet Oncol. 2018;19(3):347-57.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Polliany Roberta Dorini Pelegrina, Roseane Vasconcelos Gouveia , Antonio Vaz de Macedo, Ana Karine Vieira, Gabriela Gaspar Filgueiras Landi, Julia Lopes, Osvaldo Alves de Menezes Neto, Rafaela de Souza Ferreira, Adriana Aparecida Siviero Miachon, Rita de Cássia Barbosa da Silva Tavares , Carmem Bonfim

This work is licensed under a Creative Commons Attribution 4.0 International License.